Novel therapies for pancreatic adenocarcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-004-0050-1.pdf
Reference49 articles.
1. Jemal A, Murray T, Samuels A: Cancer statistics, 2003. CA Cancer J Clin 2003, 53(Suppl 1):5–26.
2. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576–1585.
3. Abrams RA, Lillemoe KD, Plantadosi S: Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001, 358:1565–1566.
4. Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. This trial established gemcitabine as the standard treatment for advanced pancreatic cancer. The study used clinical benefit response as its primary objective.
5. Von Hoff D, Mahadevan D, Bearss D: New developments in the treatment of patients with pancreatic cancer. Clin Oncol Updates 2001, 4:1–15.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Inhibition of hTERT in pancreatic cancer cells by pristimerin involves suppression of epigenetic regulators of gene transcription;Oncology Reports;2017-01-23
2. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-κB/mTOR prosurvival signaling;International Journal of Oncology;2016-06-29
3. CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma;International Journal of Oncology;2015-10-19
4. Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells;Oncology Reports;2015-05-19
5. Zerumbone Inhibits Angiogenesis by Blocking NF-κB Activity in Pancreatic Cancer;Pancreas;2014-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3